Log in

Amicus Therapeutics Stock Price, Forecast & Analysis (NASDAQ:FOLD)

$9.57
+0.22 (+2.35 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$9.28
Now: $9.57
$9.68
50-Day Range
$7.47
MA: $8.40
$9.62
52-Week Range
$7.11
Now: $9.57
$14.61
Volume3.07 million shs
Average Volume2.52 million shs
Market Capitalization$2.44 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.58
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FOLD
CUSIP03152W10
Phone609-662-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$91.25 million
Book Value$2.15 per share

Profitability

Net Income$-348,990,000.00
Net Margins-216.02%

Miscellaneous

Employees508
Market Cap$2.44 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.


Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its earnings results on Monday, November, 11th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.32) by $0.08. The biopharmaceutical company had revenue of $48.80 million for the quarter, compared to analyst estimates of $48.05 million. Amicus Therapeutics had a negative net margin of 216.02% and a negative return on equity of 62.61%. The firm's quarterly revenue was up 136.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.84) EPS. View Amicus Therapeutics' Earnings History.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Amicus Therapeutics.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics updated its third quarter 2019 earnings guidance on Thursday, October, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $48-48 million, compared to the consensus revenue estimate of $45.43 million.

What price target have analysts set for FOLD?

7 brokerages have issued 12 month target prices for Amicus Therapeutics' stock. Their forecasts range from $12.59 to $31.00. On average, they anticipate Amicus Therapeutics' stock price to reach $19.21 in the next twelve months. This suggests a possible upside of 100.8% from the stock's current price. View Analyst Price Targets for Amicus Therapeutics.

What is the consensus analysts' recommendation for Amicus Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amicus Therapeutics.

What are Wall Street analysts saying about Amicus Therapeutics stock?

Here are some recent quotes from research analysts about Amicus Therapeutics stock:
  • 1. According to Zacks Investment Research, "Amicus realized revenues from sales of its only marketed drug, Galafold in the second quarter. The uptake of Galafold has been strong. The company is on track to achieve its 2019 key priorities, including, Pompe late-stage development program, and the development of the gene-therapy pipeline. With a very successful, now global, commercial precision medicine product in Fabry disease, a late-stage phase III program in late onset Pompe disease and rapidly advancing gene therapy programs for rare diseases in development, the company is well positioned to achieve its target. However, it depends heavily on Galafold sales, which is a concern. Shares of the company have outperformed the industry year to date. Loss estimates narrowed ahead of Q3 earnings. The company has a dismal record of earnings surprises in the recent quarters." (11/4/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our current 12-month, $18 price target on shares of Amicus is derived from a 13-year DCF-based, sum-of-the-parts analysis driven by: beta of 1.70; terminal growth rate of 0.5%; risk premium of 4.93%; estimated WACC of 10.8%; and tax rate of 12.5% beginning in FY 2030. Galafold and AT- GAA at 42% each, plus the two Batten disease programs programs at a combined 16%, make up our rNPV. For AT-GAA, we assume a POS of 70%, whereas for CLN6 we assume a 45% POS and assign a 10% POS for CLN3." (8/1/2019)
  • 3. Cantor Fitzgerald analysts commented, "We rate Amicus Therapeutics Overweight. Amicus focuses on treatments for lysosomal storage disorders and rare diseases. We foresee Galafold as becoming the standard of care for Fabry disease patients with amenable mutations around the world. We think beyond this approval, Amicus has a robust pipeline." (2/26/2019)

Has Amicus Therapeutics been receiving favorable news coverage?

Media stories about FOLD stock have been trending somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amicus Therapeutics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the company's share price in the next several days. View News Stories for Amicus Therapeutics.

Are investors shorting Amicus Therapeutics?

Amicus Therapeutics saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 31,290,000 shares, an increase of 7.0% from the September 30th total of 29,230,000 shares. Based on an average trading volume of 3,810,000 shares, the short-interest ratio is currently 8.2 days. Currently, 12.7% of the shares of the company are short sold. View Amicus Therapeutics' Current Options Chain.

Who are some of Amicus Therapeutics' key competitors?

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Cara Therapeutics (CARA), Gilead Sciences (GILD), Celgene (CELG) and Inovio Pharmaceuticals (INO).

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the folowing people:
  • Mr. John F. Crowley, Chairman & CEO (Age 52)
  • Mr. Bradley L. Campbell, Pres, COO & Director (Age 43)
  • Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 56)
  • Dr. Jay A. Barth, Chief Medical Officer (Age 55)
  • Ms. Daphne E. Quimi, Chief Financial Officer (Age 53)

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Eagle Asset Management Inc. (1.09%), Massachusetts Financial Services Co. MA (0.55%), GW&K Investment Management LLC (0.24%), California Public Employees Retirement System (0.17%), Rhumbline Advisers (0.13%) and Assenagon Asset Management S.A. (0.09%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Burke W Whitman, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.

Which institutional investors are selling Amicus Therapeutics stock?

FOLD stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Great West Life Assurance Co. Can, Strs Ohio, First Midwest Bank Trust Division and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Hung Do, Jay Barth, John F Crowley and Michael Raab. View Insider Buying and Selling for Amicus Therapeutics.

Which institutional investors are buying Amicus Therapeutics stock?

FOLD stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Assenagon Asset Management S.A., California Public Employees Retirement System, Russell Investments Group Ltd., State of New Jersey Common Pension Fund D, SG Americas Securities LLC, GW&K Investment Management LLC and Eagle Asset Management Inc.. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $9.57.

How big of a company is Amicus Therapeutics?

Amicus Therapeutics has a market capitalization of $2.44 billion and generates $91.25 million in revenue each year. The biopharmaceutical company earns $-348,990,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Amicus Therapeutics employs 508 workers across the globe.View Additional Information About Amicus Therapeutics.

What is Amicus Therapeutics' official website?

The official website for Amicus Therapeutics is http://www.amicusrx.com/.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]


MarketBeat Community Rating for Amicus Therapeutics (NASDAQ FOLD)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  438 (Vote Outperform)
Underperform Votes:  288 (Vote Underperform)
Total Votes:  726
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel